SEC Form 4 · accession 0001567619-19-000104
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nisha Nanda
Officer — Chief Development Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 2, 2019 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $139.77 | Jan 2, 2019 | A | 37,000 | A | — | Jan 1, 2029 | Common Stock | 37,000 | 37,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable as to 1/48th of the total number of shares on February 2, 2019, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.